Skip to Main Content

Author Details

Ryan Phillips
Johns Hopkins University
2017
30
10
PMIDPaper TitleJournal TitlePublished Year
36367998Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.J Clin Oncol2023
36752776Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS.Mol Cancer Ther2023
35058322The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer: Going Beneath the Surface with Molecular Imaging.J Nucl Med2022
35680076Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysis.Radiother Oncol2022
36001857Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.J Clin Oncol2022
36244393From Idea to Clinical Practice: A Brief History of Oligometastatic Disease.Int J Radiat Oncol Biol Phys2022
36070558Cost effectiveness of treatment strategies for high risk prostate cancer.Cancer2022
36349914Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer.J Urol2022
32536574Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.Eur Urol Oncol2021
33742974Oligometastatic prostatic cancer recurrence: role of salvage lymph node dissection (sLND) and radiation therapy-stereotactic body radiation therapy (RT-SBRT).Curr Opin Urol2021
34090651Local Therapies in Oligometastatic and Oligoprogressive Prostate Cancer.Semin Radiat Oncol2021
33419682The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.Eur Urol2021
32798608Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer.Int J Radiat Oncol Biol Phys2021
32487038A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).BMC Cancer2020
31977391Radiotherapy in the Management of Metastatic Hormone-Sensitive Prostate Cancer: What Is the Standard of Care?Cancer J2020
32815993Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer-Not All That Glitters Is Gold-Reply.JAMA Oncol2020
32215577Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.JAMA Oncol2020
32544574Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.Int J Radiat Oncol Biol Phys2020
30268657Is Androgen Deprivation Therapy "Another Deficient Therapy" for Gleason Score 9-10 Prostate Cancer?Eur Urol2019
31661149Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?Oncology (Williston Park)2019
32280826Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate Cancer.Adv Radiat Oncol2019
30191396Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.World J Urol2019
31419509Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.Int J Radiat Oncol Biol Phys2019
30885363Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylations.Adv Cancer Res2019
29240543STOMPing Out Hormone-Sensitive Metastases With Local Therapies in Prostate Cancer.J Clin Oncol2018
29856697Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al.J Clin Oncol2018
29520847Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.Prostate2018
28662647A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).BMC Cancer2017
29019420What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?Future Oncol2017
29226093Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT.Urol Case Rep2017
  • 1 - 30 of 30

Recommended Authors

Robert T Dess
University of Michigan ann arbor
Career Start Year 2016
Number of shared co-authors 26
Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 12
Soumyajit Roy
Rush University Medical Center
Career Start Year 2013
Number of shared co-authors 8
R Jeffrey Karnes
Mayo Clinic
Career Start Year 2013
Number of shared co-authors 10
William C Jackson
University of Michigan ann arbor
Career Start Year 2013
Number of shared co-authors 23
Ting Martin Ma
University of Washington
Career Start Year 2010
Number of shared co-authors 25
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 2
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 14
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 4
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 4
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Career Start Year 2003
Number of shared co-authors 10
Chandana A Reddy
Cleveland Clinic
Career Start Year 2000
Number of shared co-authors 23
Michael J Morris
Memorial Sloan Kettering Cancer Center
Career Start Year 1999
Number of shared co-authors 15
Wolfgang Lilleby
Oslo University Hospital
Career Start Year 1999
Number of shared co-authors 21
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 24
Mark K Buyyounouski
Stanford University
Career Start Year 1999
Number of shared co-authors 13
Daniel J Krauss
William Beaumont School of Medicine
Career Start Year 1999
Number of shared co-authors 21
Evan Y Yu
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year 1997
Number of shared co-authors 17
Andrew Loblaw
Princess Margaret Hospital, University of Toronto
Career Start Year 1995
Number of shared co-authors 11
Xavier Maldonado
Hospital Universitari Vall d'Hebron
Career Start Year 1994
Number of shared co-authors 22
Jonathan D Tward
Huntsman Cancer Institute, University of Utah
Career Start Year 1994
Number of shared co-authors 26
Richard Choo
Mayo Clinic
Career Start Year 1991
Number of shared co-authors 20
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 16
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Career Start Year 1990
Number of shared co-authors 35
Christopher R King
University of California los angeles
Career Start Year 1988
Number of shared co-authors 17
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 18
Maha Hussain
Northwestern University
Career Start Year 1984
Number of shared co-authors 19
Mack Roach
University of California San Francisco
Career Start Year 1983
Number of shared co-authors 23
Oliver Sartor
Tulane University School of Medicine
Career Start Year 1983
Number of shared co-authors 29
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1976
Number of shared co-authors 28

Collaborators

Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 26
Matthew P Deek
Rutgers Robert Wood Johnson Medical School, Rutgers University
Co-authored papers 16
Theodore L DeWeese
Johns Hopkins University School of Medicine
Co-authored papers 11
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers 11
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 10
Danny Y Song
Johns Hopkins University School of Medicine
Co-authored papers 10
Curtiland Deville
Johns Hopkins University
Co-authored papers 10
Mario A Eisenberger
Johns Hopkins University
Co-authored papers 9
Michael A Carducci
Johns Hopkins School of Medicine
Co-authored papers 9
Channing J Paller
Johns Hopkins University School of Medicine
Co-authored papers 9
Stephen Greco
Johns Hopkins University School of Medicine
Co-authored papers 8
Piet Ost
Ghent University, GZA Ziekenhuizen
Co-authored papers 5
Bradley J Stish
Mayo Clinic
Co-authored papers 5
Ashley E Ross
Northwestern University
Co-authored papers 4
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 4
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 4
Tamara L Lotan
Johns Hopkins University School of Medicine
Co-authored papers 3
Neil B Desai
University of Texas Southwestern Medical Center
Co-authored papers 2
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Co-authored papers 2
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 2
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Co-authored papers 2
Neil R Parikh
San Antonio Cancer Center
Co-authored papers 2
Brian J Davis
Mayo Clinic
Co-authored papers 2
Amar U Kishan
University of California los angeles
Co-authored papers 2
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 2
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 1
Alexander W Wyatt
University of British Columbia
Co-authored papers 1
Neha Vapiwala
Abramson Cancer Center, University of Pennsylvania
Co-authored papers 1
Todd McNutt
Johns Hopkins University School of Medicine
Co-authored papers 1
C Richard Choo
Mayo Clinic
Co-authored papers 1
Release 1.2